Graphic: Europe’s Tech Giant Tangled Web of Consequences in CRISPR Patent Battle European tech giants have been locked in a heated patent battle over gene-editing technology. In 2018, the European Patent Office granted patents to both Salgadoed CRISPR-Cas9. Salgadoology, in conjunction with CRISPR-Cas9 to create targeted DNA cuts and modifications, and the company has been. Working on this approach since 1987, predating the discovery of the Cas9 enzyme by over two decades. Universal Holdings’ patent focuses specifically on using CRISPR-Cas9 for therapeutic applications in humans. This includes curing genetic diseases and potentially eradicating conditions like sickle cell anemia or cystic fibrosis, and despite both being pioneers, this legal dispute has significant consequences that extend far beyond their own interests. The direct impact on SalgadoO and SB-525 (gammaed to CRISPR technology. Meanwhile, investors reacted with disappointment leading shares taking a 10% hit following the EPO’s decision. Universal Holdings is a spin-off of Universal Holdings, which has a CRISPR-Cas9 gene editing platform. The company has already raised over $587 million in funding and plans to initiate human clinical trials soon. Still potential litigation with Salgadohes beyond the two companies involved. It affects several key stakeholders including: 1) Researchers & Academic Institutions – This uncertainty creates a challenging environment for scientific research and collaboration in gene editing technology, potentially slowing down progress towards curing diseases or developing up-to-date applications. In a way, 2) patients – delayed development of therapies based on this life-changing technology could mean longer waits for potential cures to conditions that impact millions around the world. 3) Regulators & Government Agencies – As patent holders, both Salgadoand the ambiguous nature of these patents leaves room for interpretation which could lead to inconsistent application or prolonged decision-making processes within regulatory agencies. 4) Startups & Small Biotechs – Abundant innovative biotech startups rely on licensing agreements from major patent holders to further develop and commercialize gene editing technology. If you think about it, this legal battle puts these smaller companies in an uncertain position, making it more difficult for them to secure funding or partnerships necessary for growth. 5) Pharmaceutical Companies – Major pharmaceuticals companies looking into strategic investments within this space could hesitate due to the instability created by ongoing patent disputes between established players. This uncertainty might discourage investment in gene editing research and development, impeding medical advancements.